ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON) (ORGANON)
Diabetes
About this trial
This is an interventional treatment trial for Diabetes focused on measuring Diabetic patients, nondiabetic patients
Eligibility Criteria
Inclusion Criteria:
- non-valvular atrial fibrillation
- nondiabetic patients
- type 1 and 2 diabetic patients
Exclusion Criteria:
- patients with cancer
- patients with chronic inflammation diseases
Sites / Locations
- IRCCS Policlinico San Matteo
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Nondiabetics (group 1)
Diabetics (group 1)
Nondiabetics (group 2)
Diabetics (group 2)
Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest